If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
GHRH analog · approved for HIV-associated lipodystrophy
Batch documentation
For Tesamorelin 10 mg sourcing, review identity, fill presentation, storage, and batch documentation before confirming a recurring program.
Overview
Tesamorelin is a 44-residue synthetic GHRH analogue carrying an N-terminal trans-3-hexenoyl modification that blocks DPP-4 cleavage and extends plasma half-life well beyond native GHRH or unmodified Sermorelin. It stands as the only FDA-approved member of the GHRH-analogue class, marketed as Egrifta for HIV-associated lipodystrophy, with the approved label specifically covering reduction of excess visceral abdominal adipose tissue in lipodystrophic HIV-positive patients. For compounding pharmacy buyers, Vialdyne releases Tesamorelin acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. At 44 residues, the sequence sits at the upper-middle of routine SPPS, and the release packet centres on peak-integration RP-HPLC plus ESI-MS confirming the N-terminal hexenoyl-modified mass, which is the diagnostic identity check. LC-MS/MS sequence verification can be included when required by an agreed pharmacy qualification protocol; the positional integrity of the hexenoyl group is load-bearing for biological activity, and intact-mass spec alone cannot localise the modification with complete confidence. Most catalogue volume moves as the standalone Tesamorelin vial for visceral-fat compounding and research, or as the pre-blended co-lyophilised Tesamorelin-plus-Ipamorelin presentation under the tesa-ipa-blend SKU for dual-pathway GH-axis preparations.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: For sterile-filled vials, confirm whether sterility, endotoxin, and CCI are included in the agreed release packet. For loose lyophilized powder, request the batch COA and separately scope any sequence-level evidence required by the buyer's written procedure.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Nasal spray listing · US inventory
Tesamorelin is also listed in this catalog as a nasal spray solution.

Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COATesamorelin 2 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATesamorelin 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATesamorelin 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COATesamorelin 20 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
Under the brand name Egrifta, the finished Tesamorelin drug carries FDA approval for HIV-associated lipodystrophy. On its own, however, the active does not appear on the 503A bulks list, and whether it can be compounded for off-label or other indications turns on the destination market's regulatory posture and shortage status at the time.
Selected literature
Frequently asked questions
Keep the sealed vial frozen at -20 C, protected from moisture, where the hexenoyl-modified peptide follows a 24-month re-test schedule with the exact date documented on the released-batch certificate. The N-terminal trans-3-hexenoyl group improves protease resistance in circulation but does not change cold-storage discipline in the vial, so treat freeze-thaw exposure as the operative stability variable once material is in hand. Storage conditions belong in the receiving record as well, since a documented temperature excursion is the kind of event that would trigger an out-of-schedule potency re-check before release to compounding.
Reconstitute the lyophilised powder in bacteriostatic water for injection at a working concentration, and because the finished preparation is injectable, do the reconstitution inside a sterile field. Draw the smallest workable single-use aliquots immediately after dissolution, since freeze-thaw cycle count is the dominant contributor to measured-potency loss for this class while gradual temperature drift matters much less. Cap cumulative thaws at three or fewer per aliquot and store at -20 C. When co-blending with a GHSR agonist under the tesa-ipa-blend SKU, work from the pre-lyophilised combination vial rather than mixing separately reconstituted components at the bench.
Yes. Tesamorelin is listed as a nasal spray solution (2 mg, 5 mg), filled in 10 mL or 20 mL bottles, with an MOQ of 10 bottles per content and fill. It is dispatched within the United States from US inventory; send an inquiry for current availability.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
29-mer
GHRH 1-29 fragment
Nasal spray listedCapsules listed
Modified GRF 1-29 · GHRH analog
Nasal spray listed
GH-axis blend (Tesamorelin + Ipamorelin), 15 mg total